The Biosecure Act, a proposed U.S. legislation, aims to significantly alter the global pharmaceutical supply chain by reducing reliance on Chinese companies, notably WuXi AppTec. This move is part of a broader strategy to address national security concerns and mitigate risks associated with foreign dependencies. WuXi AppTec, a major player in the pharmaceutical sector, is at the center of this legislative effort due to its extensive involvement in the supply chain. The Act reflects growing apprehension in the U.S. about the influence of Chinese firms in critical industries. Additionally, experts warn that advancements in artificial intelligence could facilitate the creation of new bioweapons, necessitating robust governance and oversight. Former FDA Commissioner Scott Gottlieb advocates for international cooperation to establish a regulatory body to oversee high-risk experiments and prevent potential lab leaks.